In the first study, 12 participants were looked twice at night after eating a meal medium (60 g carbohydrate) for 19 hours, were randomly assigned to use the closed-loop delivery of insulin pump or conventional insulin, and then 1-3 weeks later, one night, they used the method of delivery. In the second study, the other 12 participants were monitored twice during the night (using one of two methods of administration of insulin) after a large meal (100 g of carbohydrate) at 20:30, accompanied by alcohol.The group consisted of 24 adults (10 men and 14 women) aged 18-65 years who had used insulin pump therapy for at least three months.
These results provide further evidence that delivery overnight in a closed circuit capable of operating safely, efficiently and consistently across different age groups, insulin sensitivity, and living conditions, the authors conclude.
The time spent with glucose levels in the blood within the range increased to 28% overnight target delivery of insulin in a closed loop. Closed-circuit delivery also lowered glucose variability during the night and reduces the time spent hyperglycemic.
A team of researchers, led by Roman Hovorka of the University of Cambridge, has conducted two studies to compare the safety and efficacy of insulin in a delivery cycle during the night closed with conventional insulin pump adults with type 1 diabetes .
In an editorial, Professor Boris Kovachev from the University of Virginia, said that while the closed loop control is promising in the context of research, development and miniaturization of the system is necessary in practice to significantly improve the health and life of people with type 1 diabetes.
Two small randomized trials published in the British Medical Journal today suggests that insulin closed loop (also known as an artificial pancreas) may improve glycemic control during the night and reduce the risk of nocturnal hypoglycaemia (a sudden drop in blood sugar overnight) in adults with type 1 diabetes.
They add that the closed-loop system “may allow the future a more flexible lifestyle in conjunction with improved glycemic control for people with type 1 diabetes.”